ClinicalTrials.gg
RecruitingNCT07100730IPAX BrIGHTUpdated Nov 16, 2026

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

A Phase 3 interventional study of TLX-101-Tx + Lomustine and TLX101-Tx in Neoplastic Disease, Glioblastoma and Glioblastoma (GBM), sponsored by Telix Pharmaceuticals (Innovations) Pty Limited. Recruiting at 9 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionGlioblastomaRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glioblastoma
Why
  1. The study's listed conditions name Glioblastoma, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Telix Pharmaceuticals (Innovations) Pty Limited (part of Telix Pharmaceuticals Limited) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 16, 2026Primary completion movedStudy completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
51
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 68 studies in Glioblastoma with a site in Australia — 19 open to participants now, 29 under way, 4 of them phase 3. Glioblastoma · Australia.

Planned enrollment
36th of 64
51 · median 60
Started
2025
with 6 others
Phase 3
13 of 68
2 open now
Primary completion
2028-07
later than 20 of 28 live
Registered
64th of 68
by date
Lead sponsor
3 of 68
Telix Pharmaceuticals (Innovations) Pty Limited

Among the 68 studies in Glioblastoma with a site in Australia, this one is the 36th largest by planned enrollment of the 64 interventional ones that give a count, is one of 7 that started in 2025, is one of 13 in phase 3, reaches primary completion later than 20 of the 28 other live ones, and was the 64th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

19 of the 68 studies in Glioblastoma with a site in Australia are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 341 Glioblastoma studies recruiting now, 236 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Glioblastoma with a site in Australia, or all of them as a file.
02

Study summary

This global clinical trial which evaluates the efficacy and safety of TLX101-Tx, an investigational radiopharmaceutical therapy, in combination with lomustine versus lomustine alone in adult patients with first recurrence of glioblastoma. TLX101-Tx delivers targeted radiation to glioblastoma cells. The trial is conducted in two parts: Part 1 assesses safety and radiation dosing; Part 2 is a randomized comparison of the combination therapy against standard care.

03

Conditions studied

  • Neoplastic Disease
  • Glioblastoma
  • Glioblastoma (GBM)
  • Glioblastoma Multiform
  • Glioblastoma Multiforme, Adult
  • Glioblastoma Multiforme (GBM) WHO Grade IV

Keywords

  • Lomustine
  • Radiation Therapy
  • Radiopharmaceuticals
  • Positron-Emission Tomography
  • Brain Neoplasms
  • Glioblastoma Multiforme
  • Glioblastoma
  • GBM
  • Neoplasm Recurrence, Local
  • Central Nervous System Neoplasms
  • Brain cancer
  • Recurrent brain tumor
  • Brain tumor recurrence
  • LAT-1 targeted therapy
04

In context

Glioblastoma Reclassified

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

This study's planned enrollment of 51 is above the median of 36 across 1,756 interventional studies indexed under Glioblastoma.

Browse Glioblastoma studies →

Lead sponsor

Telix Pharmaceuticals (Innovations) Pty Limited is the lead sponsor of 22 studies on the registry; 9 are open to participants now.

Compared within Glioblastoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Previously confirmed neuropathological diagnosis of glioblastoma, IDH-wildtype according to the WHO 2021 classification.
  2. Radiographic evidence of first recurrence or progressive glioblastoma according to RANO 2.0 criteria after treatment with or maximal safe resection and standard radiotherapy or chemoradiotherapy having occurred at least 3 months after the end of prior radiotherapy. Prior first-line therapy may include a combination of:

    1. Any systemic antineoplastic treatment other than nitroureas
    2. Tumor-treating fields
    3. Conventionally fractionated or abbreviated (minimum 15 fractions) radiotherapy
  3. Increased [18F]]FET PET tracer uptake inside or in the vicinity of tumor. Specifically, amino acid-based molecular imaging using [18F]FET PET will be evaluated following co-registration with MRI. The allocated physician/reader will assess whether the observed pathologically increased amino acid uptake is located within the tumor or in the vicinity. This determination will serve as a guidance to confirm whether the uptake is tumor-associated. The uptake must be clearly discernible from background activity and measurable per PET RANO 1.0 criteria, as determined by central review.
  4. Tumor debulking for recurrent, progressive disease is allowed. The subject must have post-surgical (4-6 weeks) radiographic evidence for residual tumor according to RANO 2.0 with increased [18F] FET PET uptake and according to PET RANO 1.0.
  5. 18 years or older
  6. Have the capacity to understand the study and be willing to comply with all protocol requirements.
  7. Must have an (ECOG) Performance Status (PS) of 0-2 or ≥70
  8. Subjects on stable, not increasing dose of in the previous 7 days can be included in the study
  9. Adequate hematological, liver and renal function at the time of screening.
  10. Females of must have a negative serum pregnancy test within 7 days prior to the first dose of drug product; must not be breast-feeding; and must agree to use a highly effective method of during treatment and for 6 months following last dose of investigational product.
  11. Male subjects must agree to use condoms during sex during the treatment period and for 3 months after the last dose of the investigational drug product and must not make semen donations during treatment and for 6 months following last dose of investigational drug product. For male subjects with female partners of childbearing potential, females must agree to use a highly effective method of contraception during the treatment period and for 6 months following last dose of investigational drug product.

Exclusion criteria

Exclusion Criteria:

  1. Prior course with external beam radiation to the brain in the past 3 months. Prior treatment with brachytherapy in the brain.
  2. Treatment with bevacizumab within the prior 6 weeks.
  3. Known to imaging tracer or any product of contrast media and MRI contraindications including implanted medical devices. Unable to lie still for at least 20 min or the duration of the MRI and PET imaging or the need for general anesthesia as part of the imaging procedure.
  4. History or evidence of delayed-type -dependent chronic infection (ie, tuberculosis, systemic fungal or parasitic infection).
  5. Radiographic progression based on RANO 2.0 associated with clinical deterioration and less than 3 months.
  6. Hematological conditions, precluding catheterization or invasive procedures.
  7. illness or clinically relevant trauma within 2 weeks before the administration of the product.
  8. Known liver or kidney disease, such as hepatitis, cirrhosis, renal failure.
  9. Severe chronic or active infections (including active tuberculosis, virus, or virus infection) requiring systemic therapy.
  10. Ongoing toxicity > Grade 2 (version 5.0) from previous standard or investigational therapies.
  11. Administration of another investigational product within 90 days prior to screening.
  12. Expected non-compliance with longer-term admission at isolated nuclear medicine ward per regional regulations.
  13. Inability to complete the needed investigational and standard imaging examinations due to any reason (ie, severe claustrophobia, inability to lie still for the entire imaging time).
  14. Subjects with known phenylketonuria.
  15. Presence of any other condition that may increase the risk associated with study participation or interfere with the interpretation of study results, and, in the opinion of the study investigator, would make the subject inappropriate for entry into the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
51 participants (estimated)

Study arms

  • Experimental
    TLX101-Tx + Standard of Care

    TLX101-Tx + Lomustine

    Combination Product: TLX-101-Tx + Lomustine

  • Experimental
    TLX101-Tx Only

    TLX101-Tx Therapy only

    Radiation: TLX101-Tx

Interventions

  • Combination productTLX-101-Tx + Lomustine

    Combination therapy with TLX-101-Tx + Lomustine

    Also known as: 131I-IPA, 131I-TLX101

  • RadiationTLX101-Tx

    TLX101-Tx

    Also known as: 131I-IPA, 131I-TLX101

07

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Assessing TEAEs type according to MedDRA (Medical Dictionary for Regulatory Activities), frequency, severity according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V5.0, seriousness, and relationship of study treatment will be assessed. Laboratory abnormalities will be assessed according to the NCI CTCAE V5.0.

    Time frame: Through study completion, an average of 2 years

  2. Dose Optimization

    Part 1 of the study is being done to identify the best dose to use for Part 2 of the study

    Time frame: Through study completion, an average of 2 years

Secondary outcomes

  1. TLX101-Tx Concentration in the blood

    Monitor how TLX101-Tx and its radioactive component move through the body over time. This includes checking how much of it is found in the blood at different times.

    Time frame: From enrollment to the end of treatment at around 13 Months

  2. Radiation Dosimetry

    We will measure how much radiation from TLX101-Tx reaches the tumor and the bone marrow. This is done using special imaging scans (called SPECT, CT, and MRI) that help us see where the treatment goes in the body.

    Time frame: Through study completion, an average of 13 Months

  3. TLX101-Tx Concentration in the Urine

    Monitor how TLX101-Tx and its radioactive component move through the body over time. This includes checking how much is passed out in urine at different times following treatment.

    Time frame: From enrollment to the end of treatment at around 13 Months.

08

Study locations

7 of 9 sites recruiting
09

References and documents

Individual participant data

Plan to share: No — We have opted not to share individual participant data due to concerns regarding participant privacy and the absence of explicit consent for data sharing in the original trial protocol especially for subjects enrolled in the EU.

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jul 2028, 32 months after the start.

Of 44 phase 3 interventional studies under Glioblastoma, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 87. This study's planned 32 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Jul 2027 → Jul 2028 and completion Nov 2027 → Nov 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2025
First posted
Aug 3, 2025
StartActual
Nov 2, 2025
Primary completionEst.
Jul 2028was Jul 2027
CompletionEst.
Nov 2028was Nov 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 Belgium)
  • UZ Leuven-Gasthuisberg Campus · Leuven, Belgium
  • CHU de Liege · Liège, Belgium
Show 2 removed
  • UZ Leuven · Leuven, Belgium
  • Chu of Liège · Liège, Belgium
Nov 16, 2026
Primary completion
Jul 2027→Jul 2028
Nov 16, 2026
Study completion
Nov 2027→Nov 2028
Nov 16, 2026
Enrollment
50→51
Nov 16, 2026
Eligibility
3 inclusion criteria edited; 3 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedTumor debulking for recurrent, progressive disease is allowed. The patientsubject must have post-surgical (4-6 weeks) radiographic evidence for residual tumor according to RANO 2.0 with increased [18F] FET PET uptake and measurable disease according to PET RANO 1.0.
  • EditedPatientsSubjects on stable, not increasing dose of steroids in the previous 7 days can be included in the study
  • EditedMale patientssubjects must agree to use condoms during sex during the treatment period and for 3 months after the last dose of the investigational drug product and must not make semen donations during treatment and for 6 months following last dose of investigational drug product. For male patientssubjects with female partners of childbearing potential, females must agree to use a highly effective method of contraception during the treatment period and for 6 months following last dose of investigational drug product.
Exclusion criteria
  • EditedHemostaseologicHematological conditions, precluding catheterization or invasive procedures.
  • EditedPatientsSubjects with known phenylketonuria.
  • EditedPresence of any other condition that may increase the risk associated with study participation or interfere with the interpretation of study results, and, in the opinion of the study investigator, would make the patientsubject inappropriate for entry into the study.
Nov 16, 2026
Secondary outcomes
3 time frame changed
What changed in the outcomes
  • Time frameTLX101-Tx Concentration in the bloodFrom enrollment to the end of treatment at around 12 weeks. → From enrollment to the end of treatment at around 13 Months
  • Time frameRadiation DosimetryThrough study completion, an average of 2 years → Through study completion, an average of 13 Months
  • Time frameTLX101-Tx Concentration in the UrineFrom enrollment to the end of treatment at around 12 weeks. → From enrollment to the end of treatment at around 13 Months.
Nov 16, 2026
Contact
Study contact's phone or email changed: •••2000→•••3544; s•••@telixpharma.com→n•••@telixpharma.com; n•••@telixpharma.com→s•••@telixpharma.com. See the current contact
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 Belgium)
    • UZ Leuven-Gasthuisberg Campus · Leuven, Belgium
    • CHU de Liege · Liège, Belgium
    Show 2 removed
    • UZ Leuven · Leuven, Belgium
    • Chu of Liège · Liège, Belgium
    Primary completion Jul 2027→Jul 2028
    Study completion Nov 2027→Nov 2028
    Enrollment 50→51
    Eligibility 3 inclusion criteria edited; 3 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedTumor debulking for recurrent, progressive disease is allowed. The patientsubject must have post-surgical (4-6 weeks) radiographic evidence for residual tumor according to RANO 2.0 with increased [18F] FET PET uptake and measurable disease according to PET RANO 1.0.
    • EditedPatientsSubjects on stable, not increasing dose of steroids in the previous 7 days can be included in the study
    • EditedMale patientssubjects must agree to use condoms during sex during the treatment period and for 3 months after the last dose of the investigational drug product and must not make semen donations during treatment and for 6 months following last dose of investigational drug product. For male patientssubjects with female partners of childbearing potential, females must agree to use a highly effective method of contraception during the treatment period and for 6 months following last dose of investigational drug product.
    Exclusion criteria
    • EditedHemostaseologicHematological conditions, precluding catheterization or invasive procedures.
    • EditedPatientsSubjects with known phenylketonuria.
    • EditedPresence of any other condition that may increase the risk associated with study participation or interfere with the interpretation of study results, and, in the opinion of the study investigator, would make the patientsubject inappropriate for entry into the study.
    Secondary outcomes 3 time frame changed
    What changed in the outcomes
    • Time frameTLX101-Tx Concentration in the bloodFrom enrollment to the end of treatment at around 12 weeks. → From enrollment to the end of treatment at around 13 Months
    • Time frameRadiation DosimetryThrough study completion, an average of 2 years → Through study completion, an average of 13 Months
    • Time frameTLX101-Tx Concentration in the UrineFrom enrollment to the end of treatment at around 12 weeks. → From enrollment to the end of treatment at around 13 Months.
    Contact Study contact's phone or email changed: •••2000→•••3544; s•••@telixpharma.com→n•••@telixpharma.com; n•••@telixpharma.com→s•••@telixpharma.com. See the current contact
    + 4 other changes: identifiers, verification date, design details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07100730
Responsible party
Sponsor
First posted
Aug 3, 2025
Start date
Nov 2, 2025
Primary completion
Jul 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Clinical Project Manager
Contact
neil.smith@telixpharma.com
+61 435 963544
Back-up Clinical Project Manager
Contact
sapna.shah@telixpharma.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion